One chart in the briefing materials documented how many people during the study got COVID-19, the disease caused by the novel coronavirus. Comparing those who got the Pfizer vaccine with those in ...

With flu season underway and new, developing COVID-19 strains ... There are three types of vaccines available in the United States — Pfizer-BioNTech, Moderna and Novavax. According to the ...

The Pfizer/BioNTech coronavirus vaccine is one of two being rolled out across the UK. The government aims to vaccinate all 15 million people in the top four priority groups by mid-February and has ...

The chart below shows the most common side ... It's a small price to pay for protection against severe COVID-19: Two doses of Pfizer's vaccine lower the risk of hospitalization by roughly 90% ...

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

COVID-19 vaccine sales have declined, but other vaccines are still growth drivers for several companies. Top vaccine stocks for investors to consider include Pfizer and Moderna. Other vaccine ...

一项涉及60万完全接种疫苗人群的研究表明，辉瑞疫苗对COVID-19有94%的保护作用。 以色列最大的医疗健康机构周日报告称，在该国迄今为止最大的 ...

The new COVID-19 vaccine rolled out across the country last month, giving people access to the most recent versions of the ...

"Since its initial authorization by FDA in December 2020, the Pfizer-BioNTech COVID-19 vaccine has been administered to more than 1.5 billion people, demonstrated a favorable safety profile in all ...

The FDA already has cleared COVID-19 vaccines tweaked to better target omicron as boosters for everyone 5 and older. Pfizer's says its COVID-19 vaccine was 73% effective in protecting children ...

While these are nowhere close to the profits Pfizer saw with products such as its Covid-19 vaccine developed with BioNTech, and the antiviral treatment Paxlovid, at their peak, with weakening ...

Pfizer Inc and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side ...